BR112015020788A2 - métodos de tratamento da lesão renal aguda - Google Patents

métodos de tratamento da lesão renal aguda

Info

Publication number
BR112015020788A2
BR112015020788A2 BR112015020788A BR112015020788A BR112015020788A2 BR 112015020788 A2 BR112015020788 A2 BR 112015020788A2 BR 112015020788 A BR112015020788 A BR 112015020788A BR 112015020788 A BR112015020788 A BR 112015020788A BR 112015020788 A2 BR112015020788 A2 BR 112015020788A2
Authority
BR
Brazil
Prior art keywords
methods
renal
treatment
renal injury
injury
Prior art date
Application number
BR112015020788A
Other languages
English (en)
Portuguese (pt)
Inventor
Andress Denni
A Zager Richard
Original Assignee
Abbvie Inc
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Hutchinson Fred Cancer Res filed Critical Abbvie Inc
Publication of BR112015020788A2 publication Critical patent/BR112015020788A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7019Ischaemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7038Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112015020788A 2013-03-08 2014-03-10 métodos de tratamento da lesão renal aguda BR112015020788A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775174P 2013-03-08 2013-03-08
PCT/US2014/022688 WO2014138738A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
BR112015020788A2 true BR112015020788A2 (pt) 2017-10-10

Family

ID=51492045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020788A BR112015020788A2 (pt) 2013-03-08 2014-03-10 métodos de tratamento da lesão renal aguda

Country Status (10)

Country Link
US (1) US20160015701A1 (https=)
EP (1) EP2964671A4 (https=)
JP (1) JP2016512201A (https=)
CN (1) CN105324395A (https=)
AU (1) AU2014225320A1 (https=)
BR (1) BR112015020788A2 (https=)
CA (1) CA2901922A1 (https=)
HK (1) HK1220209A1 (https=)
MX (1) MX2015011730A (https=)
WO (1) WO2014138738A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
JP2017534634A (ja) * 2014-11-07 2017-11-24 アッヴィ・インコーポレイテッド 体液貯留の予測因子を使用してckdを処置する方法
EP3235496A1 (en) * 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
BR112019005539A2 (pt) * 2016-10-05 2019-06-18 Mitobridge, Inc. métodos de tratamento de lesão renal aguda
KR102177349B1 (ko) * 2018-02-13 2020-11-12 서울대학교병원 체세포 복제 효율 증진용 조성물
US10978176B2 (en) 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
EP4037713A4 (en) * 2019-11-06 2023-11-01 Northwestern University Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury
KR20230015874A (ko) * 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
JP2023521169A (ja) * 2020-04-10 2023-05-23 チヌーク セラピューティクス,インコーポレイテッド 糖尿病性腎疾患の処置方法
CN113209111A (zh) * 2021-05-14 2021-08-06 上海海糖生物医药科技有限公司 一种褐藻寡糖的应用
CN115005157B (zh) * 2022-06-02 2023-12-26 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN116731117B (zh) * 2023-06-19 2024-05-10 武汉大学 Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
WO2005104702A2 (en) * 2004-04-23 2005-11-10 Renal Diagnostic, Inc. An automated non- invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Also Published As

Publication number Publication date
JP2016512201A (ja) 2016-04-25
EP2964671A1 (en) 2016-01-13
WO2014138738A8 (en) 2015-12-30
US20160015701A1 (en) 2016-01-21
CN105324395A (zh) 2016-02-10
HK1220209A1 (zh) 2017-04-28
MX2015011730A (es) 2016-04-04
WO2014138738A1 (en) 2014-09-12
CA2901922A1 (en) 2014-09-12
AU2014225320A1 (en) 2015-08-06
EP2964671A4 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
BR112015020788A2 (pt) métodos de tratamento da lesão renal aguda
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
CL2015003022A1 (es) Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
AR103782A1 (es) ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
JP2016518337A5 (https=)
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
CR20160037A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
BR112017000556A2 (pt) terapia de combinação para câncer
BR112013020265A2 (pt) formas de rifaximina e uso das mesmas
BR112016026545A2 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
BR112012030621A2 (pt) compostos para o tratamento de doenças associadas com clostridim difficile
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
BR112015020199A2 (pt) usos terapêuticos para anticorpos de vegfr1
EA201591409A1 (ru) Бициклические соединения
MX2016013611A (es) Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana.
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2506 DE 15-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.